

ASX ANNOUNCEMENT

Notification of Investor Update Webcast

5th April 2016: Analytica Ltd (ASX: ALT), invites investors to webcast hosted by Geoff Daly, CEO of Analytica Limited.

The webcast will be held on **Thursday 7th April at 9am AEST.**

Following a live presentation, including pre-submitted questions, there will be a live Q&A session via webcast.

To listen to the webcast and submit questions for the live Q&A, please pre-register at this link at any time up to the commencement of the broadcast:

<https://attendee.gotowebinar.com/register/5827286656158439939>

After registering, you will receive a confirmation email containing information about joining the webinar. It is highly recommended that you click the "check system requirements" link provided in this email prior to the webinar to minimise any potential technical issues.

Alternatively, on the day and time of the webinar, please go to: www.joinwebinar.com and enter the Webinar ID: 126-027-267 and your email address.

Investors may also participate by phone in a listen only mode (questions cannot be submitted via the phone).

To access the web via telephone, you must select "Use Telephone" after joining the webinar and call in using the numbers below.

Australia: +61 2 8355 1054

Access Code: 680-898-589

Audio PIN: Shown after joining the webinar

If you would like to send a question through in advance, please email it to investorrelations@analyticamedical.com

If you have any technical issues regarding access to the webcast please also contact this address.

For more information, please contact: investorrelations@analyticamedical.com

For more information about the PeriCoach System, visit: www.PeriCoach.com

For more information about Analytica, visit www.AnalyticaMedical.com

Follow us on:





About Analytica Limited

Analytica's lead product is the PeriCoach® System – an e-health treatment system for women who suffer Stress Urinary Incontinence. This affects 1 in 3 women worldwide and is mostly caused by trauma to the pelvic floor muscles as a result of pregnancy, childbirth and menopause.

PeriCoach comprises a device, web portal and smartphone app. The device evaluates activity in pelvic floor muscles. This information is transmitted to a smartphone app and can be loaded to PeriCloud where physicians can monitor patient progress via web portal. This novel system enables physicians to remotely determine if a woman is performing her pelvic floor exercises and if these are improving her condition.

PeriCoach has regulatory clearance in Australia, and has CE mark and USFDA 510(k) clearance. The product is available for sale in Australia and New Zealand, UK and Ireland, and in the USA by prescription.